• Company concluded presentation to CPT Editorial Panel Meeting
• Awaiting announcement of panel votes in next 2-4 weeks
• Continuing focus on deployment of EchoSolv AS in the US

Echo IQ Limited (ASX: EIQ), an AI and Medical Technology company, has provided an update on its application for a Category III Current Procedural Technology (CPT) code for its EchoSolv AS product in the US. The company has concluded its presentation to the CPT Editorial Panel Meeting and is now awaiting the announcement of the panel votes, which is expected in the next 2-4 weeks. Echo IQ has advised that it has not received an indication of the panel votes at this time. The company will provide a broader update once the results are announced by the American Medical Association (AMA). In the meantime, Echo IQ will continue to focus on the ongoing deployment of EchoSolv AS with hospital groups, strategic partners, and clinics in the US. Concurrently, the company will also continue to progress FDA clearance for EchoSolv HF, new product development, and licensing and partnership opportunities for the EchoSolv technology, all of which are advancing well and in line with internal timeframes.

Echo IQ will continue to focus on the ongoing deployment of EchoSolv AS in the US, progress FDA clearance for EchoSolv HF, and pursue new product development, licensing, and partnership opportunities for its EchoSolv technology.